BioNTech präsentiert positives Daten-Update aus der Phase-1/2-Studie mit dem CAR-T-Zelltherapiekandidat BNT211 bei fortgeschrittenen soliden Tumoren auf dem ESMO-Kongress 2023
October 23, 2023 11:30 ET
|
BioNTech SE
BNT211 hat das Potential, die erste Therapie dieser Art zu werden, indem der Kandidat zwei innovative Ansätze kombiniert: eine autologe CAR-T-Zelltherapie mit dem onkofetalen Antigen Claudin-6 (CLDN6)...
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
October 23, 2023 11:30 ET
|
BioNTech SE
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T...
ESMO 2023 Coverage: Get real time insights and analysis with DelveInsight
October 20, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- ESMO 2023 Coverage: Get real time insights and analysis with DelveInsight The ESMO conference stands as a pivotal event in the oncology sphere,...
Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
October 16, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, October 16, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
BioNTech präsentiert auf dem ESMO-Kongress 2023 mehrere Programm-Updates aus verschiedenen Wirkstoffklassen
October 16, 2023 03:30 ET
|
BioNTech SE
Klinische Programm-Updates mit neuen Daten für CAR-T- und ex-vivo T-Zelltherapiekandidaten, einen innovativen ADC-Kandidaten, einen off-the-shelf Krebsimpfstoffkandidaten der FixVac-Plattform und...
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
October 16, 2023 03:30 ET
|
BioNTech SE
Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a bi-specific antibody New data from BioNTech’s...